Premium
Syringotropic hypersensitivity reaction associated with infliximab and leflunomide combination therapy in a child with psoriatic arthritis
Author(s) -
Vesel Tina,
Luzar Boštjan,
Calonje Eduardo,
Avčin Tadej
Publication year - 2009
Publication title -
journal of cutaneous pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 75
eISSN - 1600-0560
pISSN - 0303-6987
DOI - 10.1111/j.1600-0560.2008.01162.x
Subject(s) - leflunomide , medicine , infliximab , psoriatic arthritis , dermatology , rash , hypersensitivity reaction , refractory (planetary science) , arthritis , psoriasis , etanercept , immunology , pathology , methotrexate , rheumatoid arthritis , tumor necrosis factor alpha , physics , astrobiology
A 17‐year‐old boy with refractory psoriatic arthritis and alpha‐1 antitrypsin deficiency who developed a syringotropic hypersensitivity reaction after 9 months of therapy with infliximab and leflunomide is described. Clinically, our patient showed a vasculitic‐like skin rash involving both palms and soles, and histopathological examination revealed a syringotropic lymphocytic infiltrate directed toward the intra‐epidermal portion of the eccrine ducts. These features have not been previously associated with infliximab or leflunomide therapy and represent a unique cutaneous hypersensitivity reaction that does not fit any known description of an immune‐mediated hypersensitivity reaction.